Ristocetin
Structural formula | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
![]() |
|||||||||||||||||||
General | |||||||||||||||||||
Non-proprietary name | Ristocetin | ||||||||||||||||||
Molecular formula | C 95 H 110 N 8 O 44 | ||||||||||||||||||
External identifiers / databases | |||||||||||||||||||
|
|||||||||||||||||||
properties | |||||||||||||||||||
Molar mass | 2067.93 g · mol -1 | ||||||||||||||||||
safety instructions | |||||||||||||||||||
|
|||||||||||||||||||
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . |
Ristocetin (or ristomycin) is an antibiotic produced by the bacterium Amycolatopsis lurida (formerly Nocardia lurida ) and was first isolated from it in 1956. (Two components, ristocetin A and ristocetin B, with a molecular weight of about 4000 were distinguished). It used to be used for staphylococcal infections (such as spontaneous ) . Nowadays it is no longer used because of its toxicity .
Ristocetin causes platelets - agglutination in the presence of von Willebrand factor , so it is in tests for the presence or absence of this coagulation factor determining used. This is important for the diagnosis of Willebrand-Jürgens syndrome , or Bernard-Soulier syndrome . Patients with Willebrand-Jürgens syndromes have a deficiency in Von Willebrand factor, so there is little or no agglutination in the above tests . In Bernard-Soulier syndrome there is a lack of binding sites on the platelets for the von Willebrandt factor. This leads to impaired adhesion of the platelets to subendothelial structures.
Individual evidence
- ↑ Ristomycin monosulfate data sheet from Sigma-Aldrich , accessed on April 22, 2011 ( PDF ).
- ↑ Karl Wurm, AM Walter: Infectious Diseases. In: Ludwig Heilmeyer (ed.): Textbook of internal medicine. Springer-Verlag, Berlin / Göttingen / Heidelberg 1955; 2nd edition, ibid. 1961, pp. 9–223, here: p. 53.